Progentec Diagnostics

Executive Summary

Progentec Diagnostics is a US-based biotechnology company specializing in proactive care solutions for autoimmune diseases, with a focus on systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Founded in 2015 and headquartered in Oklahoma City, the company combines proprietary proteomic blood tests (e.g., aiSLE® DX) with digital health platforms like LupusCorner® to predict flares and monitor disease activity. Despite being privately held with limited public financial data, Progentec occupies a niche in autoimmune diagnostics, an area of high unmet need. The company's strategy leverages biomarker discovery and patient engagement to enable early intervention and personalized management. Key differentiators include its integrated diagnostic-digital approach and a pipeline targeting both lupus and MS. While still in growth phase, Progentec has potential to capture market share in the autoimmune diagnostics space, pending regulatory milestones and clinical adoption.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or CE marking for aiSLE® DX lupus diagnostic60% success
• Q4 2026Clinical validation data readout for MS diagnostic test50% success
• Q2 2026Strategic partnership or licensing deal with major pharma or diagnostics company40% success